ImmunoTherapyNews.net

Cancer immunotherapy

Xagena Mappa
Medical Meeting
Pneumobase.it
Ematobase.it

Search results for "Immune checkpoint inhibitors"

Treatment with the immune checkpoint inhibitor Nivolumab ( Opdivo ) has yielded durable responses in some patients with advanced non-small cell lung cancer ( NSCLC ), with a five-year survival rate of ...


Programmed cell death protein ligand-1 ( PD-L1 ) inhibitors are novel anti-cancer therapies but are associated with potentially therapy limiting immune-related adverse effects ( IRAEs ). The purpos ...


Cancer immunotherapy with checkpoint inhibitors ( CPIs ) is associated with frequent immune-related adverse events ( irAEs ) and is often not recommended for patients with concomitant autoimmune disea ...


The purpose of the study was to describe the prevalence, clinical presentation, and management of rheumatic immune‐related adverse effects ( Rh‐irAEs ) from immune checkpoint inhibitor ( ICI ) therapy ...


Hyperprogression, a paradoxical boost in tumor growth, was described in a subset of patients treated with immune checkpoint inhibitors ( ICI ). Neither clinicopathologic features nor biological mech ...


A subset of patients treated with immune checkpoint inhibitors experience an accelerated tumor growth rate ( TGR ) in comparison with pretreatment kinetics; this is known as hyperprogression. A stud ...